Browse Category

Biotechnology News 17 October 2025 - 19 October 2025

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 marketbeat.com, roughly flat

19 October 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at

19 October 2025

Biotechnology · Gene Editing · Healthcare Innovation · Investment Analysis · NASDAQ:CRSP · Stock Market

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can

18 October 2025

Biotechnology · Cancer Research · Healthcare Innovation · Investment News · NASDAQ:GRAL · Stock Market

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume

18 October 2025

Biotechnology · Investment Analysis · Leukemia Research · NASDAQ:SLS · Pharma News · Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14,

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:CMPS · NASDAQ:MNMD · NYSE:ABBV · Psychedelics · Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2%

18 October 2025

Biotechnology · Healthcare · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

Stock Soars to 52-Week High on Investor Hype MindMed’s stock has been on fire in recent weeks, vastly outperforming the broader market. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 with unusually

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:MNMD · Psychedelics · Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share benzinga.com. Year-to-date, the stock has

17 October 2025

Analyst Ratings · Biotechnology · HIV Research · Patent News · Stock Market

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

FDA Setback Triggers Strategic Review Kezar Life Sciences revealed a major regulatory setback for its lead drug and immediately pivoted to consider strategic alternatives. In an October 16 press release, the South San Francisco company announced it failed to reach

17 October 2025

Biotechnology · Company Analysis · FDA News · Investment Strategies · NASDAQ:KZR · Stock Market

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare

17 October 2025

Biotechnology · FDA Approval · Health News · Medical Breakthroughs · NASDAQ:ACHV · Nicotine Addiction

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics

17 October 2025

Biotechnology · Business News · Cancer Research · Medical Innovations · NASDAQ:GRAL · Stock Market

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior,

17 October 2025

Biotechnology · FDA Updates · Fertility · Medical Innovations · NASDAQ:FEMY · Stock Market

Previous 1 … 4 5 6 7 8 … 10 Next

Go toTop